Now that all FLT3-ITD mutated AML is classified as intermediate risk, should all eligible patients with FLT3-ITD mutated AML receive an allogeneic hematopoietic stem cell transplant (HCT) in the first CR, a strategy most beneficial in patients at the highest risk of relapse, or can transplant be reserved for first relapse or MRD positive disease? The gene discussed is FLT3; the disease is acute myeloid leukemia.